A. Dar

发表

A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK

Alma L. Burlingame, Kevan M. Shokat, Arvin C. Dar, 2011, Nature.

The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling.

K. Shokat, A. Dar, 2011, Annual review of biochemistry.

A Whole Animal Platform to Advance A Clinical Kinase Inhibitor Into New Disease Space

Avner Schlessinger, Masahiro Sonoshita, Arvin C. Dar, 2017, Nature chemical biology.

Chemical genetic discovery of targets and anti-targets for cancer polypharmacology

Kevan M. Shokat, Arvin C. Dar, Ross L. Cagan, 2012, Nature.

Higher-Order Substrate Recognition of eIF2α by the RNA-Dependent Protein Kinase PKR

Arvin C. Dar, F. Sicheri, A. Dar, 2005, Cell.

Regulated Phosphosignaling Associated with Breast Cancer Subtypes and Druggability*

Joshua F. McMichael, Adam D. Scott, Samuel H. Payne, 2019, Molecular & Cellular Proteomics.

Structural basis for the action of the drug trametinib at KSR-bound MEK

William M. Marsiglia, Mary E. Duffy, A. Dar, 2020, Nature.

Understanding and drugging RAS: 40 years to break the tip of the iceberg

A. Dar, J. Hmeljak, Donita C. Brady, 2022, Disease models & mechanisms.

Type II Binders Targeting the "GLR-Out" Conformation of the Pseudokinase STRADα.

A. Schlessinger, P. Ung, A. Dar, 2021, Biochemistry.

Chemical Genetic Approach for Kinase‐Substrate Mapping by Covalent Capture of Thiophosphopeptides and Analysis by Mass Spectrometry

A. Burlingame, Chao Zhang, K. Shokat, 2010, Current protocols in chemical biology.

A small molecule screen reveals the essentiality of p38 kinase for choanoflagellate cell proliferation

N. King, A. Dar, A. Scopton, 2022, bioRxiv.

Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR

William M. Marsiglia, R. Sebra, A. Borobia, 2022, Nature Biotechnology.

Ploidy Leads a Molecular Motor to Walk Different Paths to Drug Resistance.

William M. Marsiglia, A. Dar, Alexander M Real, 2020, Cell chemical biology.

Targeting drug-resistant mutations in ALK

A. Dar, L. He, 2022, Nature Cancer.

CNS Anticancer Drug Discovery and Development Conference White Paper.

Patrick J. Paddison, D. Berry, J. Sarkaria, 2015, Neuro-oncology.

Structure-guided inhibitor design expands the scope of analog-sensitive kinase technology.

S. Finkbeiner, Chao Zhang, K. Shokat, 2013, ACS chemical biology.

Small molecule recognition of c-Src via the Imatinib-binding conformation.

Arvin C Dar, Kevan M Shokat, K. Shokat, 2008, Chemistry & biology.

Slipped-strand DNAs formed by long (CAG)*(CTG) repeats: slipped-out repeats and slip-out junctions.

C. E. Pearson, J. Cleary, A. Dar, 2002, Nucleic acids research.

Integrated computational and Drosophila cancer model platform captures previously unappreciated chemicals perturbing a kinase network

Avner Schlessinger, Masahiro Sonoshita, Peter M U Ung, 2018, bioRxiv.

Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling

A. Dar, N. Dhawan, A. Scopton, 2016, Nature.

A pickup in pseudokinase activity.

A. Dar, 2013, Biochemical Society transactions.

X-ray crystal structure and functional analysis of vaccinia virus K3L reveals molecular determinants for PKR subversion and substrate recognition.

F. Sicheri, A. Dar, 2002, Molecular cell.

PyVOL: a PyMOL plugin for visualization, comparison, and volume calculation of drug-binding sites

Avner Schlessinger, Arvin C. Dar, Ryan H.B. Smith, 2019, bioRxiv.

Formin Leaky Cap Allows Elongation in the Presence of Tight Capping Proteins

Charles Boone, S. Zigmond, F. Sicheri, 2003, Current Biology.

Mechanistic Link between PKR Dimerization, Autophosphorylation, and eIF2α Substrate Recognition

Arvin C. Dar, Keiko Ozato, F. Sicheri, 2005, Cell.

Endoplasmic reticulum stress-independent activation of unfolded protein response kinases by a small molecule ATP-mimic

K. Shokat, P. Walter, A. Dar, 2015, eLife.

CNS Anticancer Drug Discovery and Development: 2016 conference insights.

P. Tonge, V. Levin, W. Weiss, 2017, CNS oncology.

PKR and GCN2 Kinases and Guanine Nucleotide Exchange Factor Eukaryotic Translation Initiation Factor 2B (eIF2B) Recognize Overlapping Surfaces on eIF2α

F. Sicheri, A. Dar, C. Cao, 2005, Molecular and Cellular Biology.

Protein kinase PKR mutants resistant to the poxvirus pseudosubstrate K3L protein

F. Sicheri, A. Dar, C. Cao, 2008, Proceedings of the National Academy of Sciences.

Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology

Mary E. Duffy, E. Guccione, A. Dar, 2019, Molecular Cancer Therapeutics.

Hepatitis C virus genetics affects miR-122 requirements and response to miR-122 inhibitors

A. Bashir, Benjamin Israelow, A. Dar, 2014, Nature Communications.

Structural basis for the action of the drug trametinib at KSR-bound MEK

Mary E. Duffy, A. Dar, Arthur Chow, 2020, Nature.

WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma

Mary E. Duffy, J. Llovet, E. Guccione, 2023, Nature Cancer.

RASopathy mutations open new insights into the mechanism of BRAF activation.

A. Dar, Donita C. Brady, 2022, Molecules and Cells.

The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers

A. Dar, M. S. Ritorto, Meagan B Ryan, 2024, Cancer discovery.

Live-cell target engagement of allosteric MEKi on MEK-RAF/KSR-14-3-3 complexes.

A. Dar, William Marsiglia, Arthur Chow, 2023, Nature chemical biology.